ArticleNPJ breast cancer2024

Gedatolisib shows superior potency and efficacy versus single-node PI3K/AKT/mTOR inhibitors in breast cancer models.

Stefano Rossetti et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.